Accessibility Menu
Virax Biolabs Group logo

Virax Biolabs Group(NASDAQ) VRAX

Market Cap$2.25MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2022)-100%
5 YearN/A
1 Year-85%
1 Month-25%
$2.81
-0.36%
-0.01Today
Virax Biolabs Group last closing stock price
MetricPriceDate
Last closeUSD 2.822026-08-13
Virax Biolabs Group stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+1.81%USD 2.772026-08-06
1 month-24.6%USD 3.742026-07-14
3 month-26.51%USD 3.842026-05-15
Year to date-67.38%USD 8.652025-12-31
1 year-84.96%USD 18.762025-08-13
3 year-96.78%USD 87.502023-08-14
Since inception-99.94%USD 4,550.002022-07-21

Virax Biolabs Group Financials at a Glance

Market Cap

$2.25MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$20.36K

Net Income (TTM)

-$13.42M

EPS (TTM)

-$16.91

P/E Ratio

-0.17

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$2.81

Volume

30,380.498

Open

$2.85

Previous Close

$2.82

Daily Range

$2.83 - $2.89

52-Week Range

$2.50 - $21.75

Estimated Earnings Date

Jul 1, 2026

VRAX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Virax Biolabs Group

Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses and diagnosis of viral diseases. The company is developing T cell-based test technologies aimed at supporting an immunology profiling platform, with potential applications in post-acute infection syndromes, including Long COVID.

Products and Services
  • T cell-based test technologies for immune response detection
  • Immunology profiling platform for chronic conditions
  • Diagnostic solutions for viral diseases
Growth Outlook
  • Market demand for immune response diagnostics is increasing
  • Potential applications in Long COVID and other chronic conditions
  • Expansion of product offerings to meet diverse healthcare needs
Financial Highlights
  • Recent quarterly revenue of 10,815, reflecting growth potential
  • Cash and short-term investments of 6,518,205, providing operational flexibility
  • Current ratio of 9.97 indicates strong liquidity position
Virax Biolabs Group Limited operates in a rapidly evolving biotechnology sector, focusing on innovative solutions for viral disease diagnostics. The company's commitment to developing advanced testing technologies positions it well to capitalize on the growing demand for immune response diagnostics, particularly in the context of Long COVID and other chronic conditions. With a robust cash position and a strong current ratio, the company is well-equipped to navigate the challenges of the biotechnology landscape while pursuing its growth objectives.
AI Generated • Jul 26, 2026

Industry

Healthcare Providers and Services

Sector

Health Care

Employees

26

CEO

James Foster

Website

www.viraxbiolabs.com

Headquarters

Lanarkshire, SC ML1 5UH, GB

VRAX Financials

Key Financial Metrics (TTM)

Gross Margin

-1480.46%

Operating Margin

-64038.24%

Net Income Margin

-52473.24%

Return on Equity

-114.24%

Return on Capital

-80.08%

Return on Assets

-88.44%

Earnings Yield

-5.88%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.25MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

797.00K

Volume

30.38K

Avg. Volume

2.16M

Financials (TTM)

Gross Profit

-$260.79K

Operating Income

-$15.15M

EBITDA

-$13.78M

Operating Cash Flow

-$12.11M

Capital Expenditure

-$1.00M

Free Cash Flow

-$13.11M

Cash & ST Invst.

$6.52M

Total Debt

$414.39K

Virax Biolabs Group Performance Analysis

Virax Biolabs Group annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31USD 8,561N/A
20242024-03-31USD 156,4191727.1%
20252025-03-31USD 6,331-96.0%
20262026-03-31USD 12,42396.2%
Virax Biolabs Group sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-09-30-93.8%
Q42025-03-31-72.2%
Q22025-09-3016.7%
Q42026-03-31672.6%
Virax Biolabs Group annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31USD -128.35241.7%
20242024-03-31USD -83.90-34.6%
20252025-03-31USD -40.62-51.6%
20262026-03-31USD -12.64-68.9%
Virax Biolabs Group sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-09-3048.0%
Q42025-03-3114.6%
Q22025-09-3035.5%
Q42026-03-31-3.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

$12.42K

-84.5%

Gross Profit

$7.69K

-80.8%

Gross Margin

61.90%

N/A

Market Cap

$2.25MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$86.44K

N/A

Employees

26

N/A

Net Income

-$5.02M

-31.4%

EBITDA

-$5.51M

-48.0%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

$6.52M

+81.6%

Total Debt

$414.39K

+84.7%

Accounts Receivable

$0.00

-100.0%

Inventory

$48.04K

-20.4%

Long Term Debt

$304.81K

+72.8%

Short Term Debt

$109.58K

+128.5%

Return on Assets

-88.44%

N/A

Return on Invested Capital

-1.18%

N/A

Free Cash Flow

-$4.88M

-50.1%

Operating Cash Flow

-$4.62M

-65.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ARTLArtelo Biosciences, Inc.
$0.80+5.48%
NCELNewcelX Ltd.
$3.32-7.78%
DRMADermata Therapeutics, Inc.
$1.47-6.37%
ATXIAvenue Therapeutics, Inc.
$0.28+10.02%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$15.21+0.09%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.60-0.00%
ONDSOndas
$9.20+0.03%
INTCIntel
$103.10-0.01%

Questions About VRAX

What is the current price of Virax Biolabs Group?

Virax Biolabs Group is trading at $2.83 per share.

What is the 52-week range for Virax Biolabs Group?

Over the past 52 weeks, Virax Biolabs Group has traded between $2.50 and $21.75.

How much debt does Virax Biolabs Group have?

As of the most recent reporting period, Virax Biolabs Group reported total debt of $414.39K.

How much cash does Virax Biolabs Group have on hand?

Virax Biolabs Group reported $6.44M in cash and cash equivalents in its most recent financial results.

What is Virax Biolabs Group’s dividend yield?

Virax Biolabs Group does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services